Evolution of breast cancer treatments: Current options and quality-of-life considerations

European Journal of Oncology Nursing

Volumn 8, Issue SUPPL. 2, 2004, Pages

  Fallowfield, Lesley J ^a  

^a BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

Breast cancer; Faslodex; Fulvestrant; Goserelin; Quality of life; Zoladex

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; ARZOXIFENE; CLONIDINE; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; DROLOXIFENE; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR BLOCKING AGENT; EXEMESTANE; FLUOROURACIL; FORMESTANE; FULVESTRANT; GABAPENTIN; GESTAGEN; GONADORELIN; GONADORELIN AGONIST; GOSERELIN; HORMONE RECEPTOR BLOCKING AGENT; IDOXIFENE; LETROZOLE; MEGESTROL ACETATE; METHOTREXATE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ABDOMINAL PAIN; ACNE; ADVANCED CANCER; ARTICLE; ASTHENIA; BODY WEIGHT DISORDER; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPNEA; EDEMA; ENDOMETRIUM CANCER; FEMALE; FLUID RETENTION; HIRSUTISM; HOT FLUSH; HUMAN; INJECTION SITE REACTION; MEDICAL DECISION MAKING; NAUSEA; OVARIECTOMY; PARTIAL BODY RADIATION; POSTMENOPAUSE; PREMENOPAUSE; QUALITY OF LIFE; QUESTIONNAIRE; SEDATION; SELF REPORT; SIDE EFFECT; SYMPTOM; THROMBOEMBOLISM; TREATMENT PLANNING; URINARY TRACT DISEASE; VAGINA BLEEDING; VAGINA DISEASE; VASODILATATION; VOMITING; WEIGHT GAIN; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; MASTECTOMY; MORTALITY; PROCEDURES; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME; UNITED KINGDOM;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR MODULATORS; FEMALE; GREAT BRITAIN; HUMANS; MASTECTOMY; QUALITY OF LIFE; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 8344242903     PISSN: 14623889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejon.2004.09.005     Document Type: Article

References (48)

1. G.T. Beatson On the treatment of inoperable cases of carcinogen of the mamma: Suggestions for a new method of treatment, with illustrative cases Lancet 2 1896 105-107
2. J. Bonneterre A. Buzdar J.M. Nabholtz J.F. Robertson B. Thürlimann M. von Euler T. Sahmoud A. Webster M. Steinberg Arimidex Writing Committee, Investigators Committee Members Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma Cancer 92 2001 2247-2258
3. A.U. Buzdar Endocrine therapy in the treatment of metastatic breast cancer Seminars in Oncology 28 2001 291-304
4. A.U. Buzdar C. Marcus F. Holmes Phase II evaluation of LY156758 in metastatic breast cancer Oncology 45 1988 344-345
5. A. Buzdar J. Douma N. Davidson R. Elledge M. Morgan R. Smith L. Porter J. Nabholtz X. Xiang C. Brady Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate Journal of Clinical Oncology 19 2001 3357-3366
6. A.U. Buzdar J. O'Shaughnessy C. Hudis D. Booser J. Pippen S. Jones P. Munster N. Enas A. Melemed E. Winer A.M. Storniolo Preliminary results of a randomized double-blind phase II study of the selective estrogen receptor modulator (SERM) arzoxifene in patients with locally advanced or metastatic breast cancer Proceedings of the American Society of Clinical Oncology 20 2001 45a, abs 178
7. A. Buzdar D. Hayes A. El-Khoudary S. Yan P. Lønning M. Lichinitser R. Gopal G. Falkson K. Pritchard A. Lipton K. Wolter A. Lee K. Fly R. Chew M. Alderdice K. Burke P. Eisenber Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer Breast Cancer Research and Treatment 73 2002 161-175
8. M. Castiglione-Gertsch A. O'Neill K.N. Price A. Goldhirsch A.S. Coates M. Colleoni M.L. Nasi M. Bonetti R.D. Gelber Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial Journal of the National Cancer Institute 95 2003 1833-1846
9. R.T. Chlebowski J.A. Kim N.F. Col Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy Seminars in Oncology 30 2003 776-788
10. I.A. Cohen J.H. Keller M.A. Abate Management of breast cancer Clinical Pharmacology 1 1982 515-529
11. S. Coster L.J. Fallowfield The impact of endocrine therapy on patients with breast cancer: A review of the literature Breast 11 2002 1-12
12. N.E. Davidson A. O'Neill A. Vukov C.K. Osborne S. Martino D. White M. Abeloff for the Eastern Cooperative Oncology Group Chemohormonal therapy in premenopausal node-positive, receptor-positive breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101) Proceedings of the American Society of Clinical Oncology 22 2003 5, abs 15
13. H. De Haes M. Olschewski M. Kaufmann M. Schumacher W. Jonat W. Sauerbrei Quality of life in goserelin-treated versus cyclophosphamide+methotrexate+fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: The zoladex early breast cancer research association trialists group Journal of Clinical Oncology 21 2003 4510-4516
14. P. Dombernowsky I. Smith G. Falkson R. Leonard L. Panasci J. Bellmunt W. Bezwoda G. Gardin A. Gudgeon M. Morgan A. Fornasiero W. Hoffmann J. Michel T. Hatschek T. Tjabbes H.A. Chaudri U. Hornberger P.F. Trunet Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate Journal of Clinical Oncology 16 1998 453-461
15. Early Breast Cancer Trialists' Collaborative Group Ovarian ablation in early breast cancer: Overview of the randomised trials Lancet 348 1996 1189-1196
16. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: An overview of the randomised trials Lancet 351 1998 1451-1467
17. M. Espie Megestrol acetate in advanced breast carcinoma Oncology 51 Suppl 1 1994 8-12
18. L. Fallowfield Quality of life: A new perspective for cancer patients Nature Reviews Cancer 2 2002 873-879
19. L.J. Fallowfield R. McGurk Same gain, less pain: Potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer European Journal of Cancer 40 2004 2403-2410
20. D. Fellowes L.J. Fallowfield C.M. Saunders J. Houghton Tolerability of hormone therapies for breast cancer: How informative are documented symptom profiles in medical notes for 'well-tolerated' treatments? Breast Cancer Research and Treatment 66 2001 73-81
21. B. Fisher J.P. Costantino C.K. Redmond E.R. Fisher D.L. Wickerham W.M. Cronin Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 Journal of the National Cancer Institute 86 1994 527-537
22. GLOBOCAN, 2000. Cancer incidence, mortality and prevalence worldwide, version 1.0. Available at www-dep.iarc.fr/globocan/globocan.html [Accessed 19 Mar 2004].
23. P.E. Goss T.J. Powles M. Dowsett G. Hutchison A.M. Brodie J.C. Gazet R.C. Coombes Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: Phase II report Cancer Research 46 1986 4823-4826
24. W.J. Gradishar J.E. Glusman C.L. Vogel J.L. Mansi N.S.A. Stuart J. Carmichael D. Elling K.R. Kunz G.W. Sledge Raloxifene HCI, a new endocrine agent, is active in estrogen receptor positive (ER+) metastatic breast cancer Breast Cancer Research and Treatment 20 Suppl 1997 53
25. A. Haddow J.M. Watkinson E. Paterson Influence of synthetic oestrogens upon advanced malignant disease British Medical Journal 2 1944 393-398
26. K. Holli R. Valavaara G. Blanco V. Kataja P. Hietanen M. Flander E. Pukkala H. Joensuu Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group Journal of Clinical Oncology 18 2000 3487-3494
27. A. Howell J.F.R. Robertson J. Quaresma Albano A. Aschermannova L. Mauriac U.R. Kleeberg I. Vergote B. Erikstein A. Webster C. Morris Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment Journal of Clinical Oncology 20 2002 3396-3403
28. J.N. Ingle D.L. Ahmann S.J. Green J.H. Edmonson H.F. Bisel L.K. Kvols W.C. Nichols E.T. Creagan R.G. Hahn J. Rubin S. Frytak Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer New England Journal of Medicine 304 1981 16-21
29. R. Jakesz H. Hausmaninger E. Kubista M. Gnant C. Menzel T. Bauernhofer M. Seifert K. Haider B. Mlineritsch P. Steindorfer W. Kwasny M. Fridrik G. Steger V. Wette H. Samonigg Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group Trial 5 Journal of Clinical Oncology 20 2002 4621-4627
30. S.R. Johnston V. Gorbunova M. Lichinitser G. Manikas P. Koralewski A. Pluzanska A. Garin E. Harvey International Idoxifene Study Group A multicentre double-blind randomised phase III trial of idoxifene versus tamoxifen as first-line endocrine therapy for metastatic breast cancer Proceedings of the American Society of Clinical Oncology 20 2001 29a, abs 113
31. W. Jonat M. Kaufmann W. Sauerbrei R. Blamey J. Cuzick M. Namer I. Fogelman J.C. de Haes A. De Matteis A. Stewart W. Eiermann I. Szakolczai M. Palmer M. Schumacher M. Geberth B. Lisboa Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study Journal of Clinical Oncology 20 2002 4628-4635
32. M. Kaufmann W. Jonat R. Blamey J. Cuzick I. Fogelman J. De Haes M. Namer W. Sauerbrei M. Schumacher Updated survival results from the Zebra trial Breast Cancer Research and Treatment 76 Suppl 1 2002 S73, abs 254
33. M. Kaufmann W. Jonat J. Blamey J. Cuzick I. Namer I. Fogelman J. De Haes M. Schumacher W. Sauerbrei Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists Group Survival analyses from the ZEBRA study: Goserelin (Zoladex™) versus CMF in premenopausal women with node-positive breast cancer European Journal of Cancer 39 2003 1711-1717
34. L.B. Michaud A.U. Buzdar Risks and benefits of aromatase inhibitors in postmenopausal breast cancer Drug Safety 21 1999 297-309
35. H. Mouridsen M. Gershanovich Y. Sun R. Perez-Carrion C. Boni A. Monnier J. Apffelstaedt R. Smith H.P. Sleeboom F. Jaenicke A. Pluzanska M. Dank D. Becquart P.P. Bapsy E. Salminen R. Snyder H. Chaudri-Ross R. Lang P. Wyld A. Bhatnagar Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group Journal of Clinical Oncology 21 2003 2101-2109
36. J.M. Nabholtz Steroidal side effects of exemestane Journal of Clinical Oncology 19 2001 2107-2108
37. C.K. Osborne J. Pippen S.E. Jones L.M. Parker M. Ellis S. Come S.Z. Gertler J.T. May G. Burton I. Dimery A. Webster C. Morris R. Elledge A. Buzdar Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial Journal of Clinical Oncology 20 2002 3386-3395
38. P.P. Peethambaram J.N. Ingle V.J. Suman L.C. Hartmann C.L. Loprinzi Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis Breast Cancer Research and Treatment 54 1999 117-122
39. N. Perez J. Borja Aromatase inhibitors: Clinical pharmacology and therapeutic implications in breast cancer Journal of International Medical Research 20 1992 303-312
40. D. Plotkin J.J. Lechner W.E. Jung P.J. Rosen Tamoxifen flare in advanced breast cancer Journal of the American Medical Association 240 1978 2644-2646
41. T.J. Powles T. Hickish J.A. Kanis A. Tidy S. Ashley Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women Journal of Clinical Oncology 14 1996 78-84
42. S. Pyrhonen J. Ellmen J. Vuorinen M. Gershanovich T. Tominaga M. Kaufmann D.F. Hayes Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer Breast Cancer Research and Treatment 56 1999 133-143
43. J.F. Robertson C.K. Osborne A. Howell S.E. Jones L. Mauriac M. Ellis U.R. Kleeberg S.E. Come I. Vergote S. Gertler A. Buzdar A. Webster C. Morris Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women - a prospective combined analysis of two multicenter trials Cancer 98 2003 229-238
44. C. Rose O. Vtoraya A. Pluzanska N. Davidson M. Gershanovich R. Thomas S. Johnson J.J. Caicedo H. Gervasio G. Manikhas F. Ben Ayed S. Burdette-Radoux H.A. Chaudri-Ross R. Lang An open randomised trial of second-line endocrine therapy in advanced breast cancer: Comparison of the aromatase inhibitors letrozole and anastrozole European Journal of Cancer 39 2003 2318-2327
45. J.R. Sainsbury T.J. Anderson D.A. Morgan ABC of breast diseases: Breast cancer British Medical Journal 321 2000 745-750
46. C. Savage J.L. Pater T. Dongsheng B. Norris He said/she said: How much agreement is there on symptoms between common toxicity criteria and quality of life? Proceedings of the American Society of Clinical Oncology 21 2002 386a, abs 1540
47. C.L. Vogel I. Shemano J. Schoenfelder R.A. Gams M.R. Green Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer Journal of Clinical Oncology 11 1993 345-350
48. A.E. Wakeling Similarities and distinctions in the mode of action of different classes of antioestrogens Endocrine-Related Cancer 7 2000 17-28